Cellcom Israel

3.77

0.0000

Volume:- -

Turnover:- -

Market Cap:613.66M

PE:-10.29

High:3.77

Open:3.77

Low:3.77

Close:3.77

52wk High:5.49

52wk Low:1.86

Shares:162.78M

Float Shares:84.30M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.3664

EPS(LYR):-0.2617

ROE:-10.15%

ROA:-0.17%

PB:1.18

PE(LYR):-14.41

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks

Dow Jones

·

Feb 18, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CEL"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEL\",,,,,undefined,":{"symbol":"CEL","market":"US","secType":"STK","nameCN":"Cellcom Israel","latestPrice":3.77,"timestamp":1612818000000,"preClose":3.77,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":84298091,"shares":162775715,"eps":-0.366397,"marketStatus":"Delisted","change":0,"latestTime":"02-08 16:00:00 EST","open":3.77,"high":3.77,"low":3.77,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.366397,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1170738000000,"exchange":"NYSE","adjPreClose":3.77,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CEL\",,,,,undefined,":{"symbol":"CEL","floatShares":84298091,"roa":"-0.17%","roe":"-10.15%","lyrEps":-0.261688,"shares":162775715,"dividePrice":0,"high":3.77,"amplitude":0,"preClose":3.77,"low":3.77,"week52Low":1.86,"pbRate":"1.18","week52High":5.49,"institutionHeld":0,"latestPrice":3.77,"eps":-0.366397,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.366397,"open":3.77},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2021-02-09","symbol":"CEL","reason":null,"defaultRemindTime":1612881000000,"announcedDate":"2021-02-04","type":"delisting","dateTimestamp":1612846800000},{"market":"US","date":"2020-11-23","symbol":"CEL","fiscalQuarterEnding":"2020/09","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1606107600000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2020-08-17","symbol":"CEL","fiscalQuarterEnding":"2020/06","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1597636800000,"reportTimeType":"","actualEps":-0.09},{"market":"US","date":"2020-05-21","symbol":"CEL","fiscalQuarterEnding":"2020/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1590033600000,"reportTimeType":"","actualEps":-0.08},{"market":"US","date":"2020-03-23","symbol":"CEL","fiscalQuarterEnding":"2019/12","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1584936000000,"reportTimeType":"","actualEps":-0.12}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CEL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CEL\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2512157767","title":"Press Release: CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2512157767","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512157767?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:30","pubTimestamp":1739885400,"startTime":"0","endTime":"0","summary":"CEL-SCI Reports Fiscal Q1 2025 Financial Results: Multikine Shows Pre-Surgical Tumor Elimination and Regression in Just 3 Weeks. CEL-SCI Corporation  today reported financial results for three months ended December 31, 2024, as well as key recent clinical and corporate developments.\"CEL-SCI is very uniquely positioned at this moment as an immuno-oncology company with a vast amount of data from the largest Phase 3 head and neck cancer study ever performed, with statistically significant evidence that our drug can successfully fight cancer and extend lives in head and neck cancer,\" stated CEL-SCI CEO, Geert Kersten. \"We hope to deliver a new standard of care to patients while substantially transforming our company's valuation to reflect what we believe to be the intrinsic value of our cancer drug. The statistical analysis shows that our very soon to be initiated small confirmatory Registration Study has a very high chance of success and we will have indications of efficacy as early as 20","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4023","BK4139","CVM","BK4528","BK4585","SAP","CEL"],"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":34,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CEL\",params:#limit:6,delay:false,,,undefined,":[]}}